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1. BACKGROUND {#tid13348-sec-0001}
=============

Severe acute respiratory syndrome coronavirus 2 (named SARS CoV‐2/COVID‐19) is a novel pandemic infectious disease, which emerged in Wuhan, China, in late December 2019 and spread rapidly worldwide.[^1^](#tid13348-bib-0001){ref-type="ref"}, [^2^](#tid13348-bib-0002){ref-type="ref"} At the time we are writing (05/10/2020), in Italy there are about 219 000 patients infected, 28 600 only in Piedmont, our region.[^3^](#tid13348-bib-0003){ref-type="ref"} Clinically, the disease is characterized with fever, cough, dyspnea, diarrhea, and eventually respiratory failure.[^4^](#tid13348-bib-0004){ref-type="ref"}, [^5^](#tid13348-bib-0005){ref-type="ref"} According to their intrinsic frailty and comorbidities, transplanted patients were considered a high‐risk population.[^6^](#tid13348-bib-0006){ref-type="ref"}, [^7^](#tid13348-bib-0007){ref-type="ref"}

Tocilizumab (TCZ), a humanized monoclonal antibody against interleukin‐6 (IL‐6) receptor widely adopted in adult rheumatoid arthritis and also used as rescue therapy for chronic antibody‐mediated rejection in kidney transplantation,[^8^](#tid13348-bib-0008){ref-type="ref"} has been recently registered for the treatment of severe or life‐threatening chimeric antigen receptor T--cell induced cytokine release syndrome (CRS) in adult and pediatric patients.[^9^](#tid13348-bib-0009){ref-type="ref"} In this context, because the development of acute respiratory distress syndrome (ARDS) in COVID‐19 pneumonia has been associated with activation of the immune system and consequent cytokine storm with high levels of IL‐6, some initial reports suggested a beneficial role of this drug,[^10^](#tid13348-bib-0010){ref-type="ref"}, [^11^](#tid13348-bib-0011){ref-type="ref"} also in solid organ transplanted patients.[^12^](#tid13348-bib-0012){ref-type="ref"} Herein, we reported our experience in 6 kidney transplanted patients treated with TCZ after occurrence of COVID‐19 infection.

2. CASE SERIES {#tid13348-sec-0002}
==============

Clinical characteristics and laboratory data are shown in Tables [1](#tid13348-tbl-0001){ref-type="table"} and [2](#tid13348-tbl-0002){ref-type="table"}. Figure [1](#tid13348-fig-0001){ref-type="fig"} reported the timeline of maintenance immunosuppression, COVID‐19‐specific treatments, and outcome. In all patients, diagnosis was performed by nasopharyngeal swab test (PCR) and chest radiography or high‐resolution computed tomography (HRCT). TCZ was administered once daily for two consecutive days (dose 8 mg/kg) after a consultation with infectious disease specialist in patients with contemporary evidence of pulmonary involvement (oxygen saturation---Sa02---\<93% if patients breath ambient air, or a ratio of the partial pressure of oxygen---PaO2---to the fraction of inspired oxygen---FiO2---of less than 300 mm Hg) and pro‐inflammatory profile (C‐reactive protein and/or IL‐6 \> × 10 normal values). All patients gave written informed consent for TCZ off‐label use.

###### 

Clinical characteristics, comorbidities, and symptoms at presentation in our COVID‐19‐positive kidney transplant recipients

                                                           Patient 1   Patient 2   Patient 3   Patient 4   Patient 5   Patient 6
  -------------------------------------------------------- ----------- ----------- ----------- ----------- ----------- -----------
  Gender                                                   Male        Male        Male        Male        Male        Male
  Age, years                                               41          65          54          62          49          62
  Previous KT (n)                                          No          Yes (1)     Yes (2)     Yes (1)     No          No
  Time from last KT, days                                  5354        8           2053        4681        6411        3163
  Comorbidities                                                                                                        
  Hypertension                                             Yes         Yes         No          Yes         No          Yes
  Diabetes mellitus                                        No          Yes         No          No          No          No
  Cardiovascular disease                                   No          Yes         Yes         Yes         Yes         Yes
  HCV infection[^a^](#tid13348-note-0003){ref-type="fn"}   No          No          No          Yes         Yes         No
  Immunosuppressive therapy                                                                                            
  TAC                                                      Yes         Yes         Yes         Yes         Yes         Yes
  MMF                                                      No          Yes         No          Yes         Yes         No
  Steroids                                                 Yes         Yes         Yes         Yes         Yes         Yes
  Symptoms at presentation                                                                                             
  Fever                                                    Yes         Yes         Yes         Yes         Yes         Yes
  Cough                                                    Yes         Yes         No          No          Yes         No
  Dyspnea                                                  No          No          No          Yes         No          Yes
  Diarrhea                                                 No          No          Yes         Yes         No          No

Abbreviations: KT, kidney transplant; MMF, mycophenolate mofetil; TAC, tacrolimus.

Negative HCV‐RNA in both cases after eradication.
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###### 

Laboratory and pulmonary functional tests before and after TCZ adoption in our COVID‐19‐positive kidney transplant recipients

                                                                                      Patient 1        Patient 2        Patient 3                                        Patient 4                                         Patient 5       Patient 6
  ----------------------------------------------------------------------------------- ---------------- ---------------- ------------------------------------------------ ------------------------------------------------- --------------- ------------------------------------------------
  C‐reactive protein (mg/L)                                                                                                                                                                                                                
  Before TCZ                                                                          170.4            90.2             154.7                                            32                                                49.8            71.4
  Day 3 after TCZ                                                                     35.4             20.3             44.6                                             12                                                23.7            8.6
  At last f/up                                                                        3.6              34.9             2.24                                             10                                                0.6             2.4
  Procalcitonin (ng/mL)                                                                                                                                                                                                                    
  Before TCZ                                                                          24.1             0.19             0.18                                             0.12                                              0.43            0.4
  Day 3 after TCZ                                                                     1.02             0.1              0.3                                              0.13                                              0.29            NA
  At last f/up                                                                        0.17             0.73             0.07                                             0.15                                              0.06            0.45
  Whyte‐cell count \[lymphocyte\] (per mm[^3^](#tid13348-bib-0003){ref-type="ref"})                                                                                                                                                        
  Before TCZ                                                                          9930 \[400\]     7240 \[370\]     4380 \[610\]                                     13 660 \[230\]                                    4130 \[300\]    7890 \[480\]
  Day 3 after TCZ                                                                     11 300 \[230\]   6270 \[310\]     4020 \[800\]                                     21 790 \[400\]                                    4370 \[330\]    4110 \[140\]
  At last f/up                                                                        6390 \[850\]     11 720 \[410\]   3770 \[950\]                                     36 890 \[800\]                                    6440 \[1030\]   10 420 \[380\]
  Lactate dehydrogenase (UI/L)                                                                                                                                                                                                             
  Before TCZ                                                                          771              518              652                                              704                                               573             1068
  Day 3 after TCZ                                                                     496              792              765                                              565                                               762             816
  At last f/up                                                                        480              660              603                                              814                                               779             739
  D‐Dimer (ng/mL)                                                                                                                                                                                                                          
  Before TCZ                                                                          12 552           707              730                                              3188                                              876             351
  Day 3 after TCZ                                                                     18 111           1497             840                                              2873                                              2020            \<215
  At last f/up                                                                        1565             2032             500                                              2842                                              1468            281
  Ferritin (ng/mL)                                                                                                                                                                                                                         
  Before TCZ                                                                          1754             523              NA                                               830                                               1567            955
  Day 3 after TCZ                                                                     1108             847              NA                                               637                                               1065            767
  At last f/up                                                                        1310             906              NA                                               840                                               371             NA
  IL‐6 (pg/mL)                                                                                                                                                                                                                             
  Before TCZ                                                                          NA               NA               24.9[^a^](#tid13348-note-0005){ref-type="fn"}    465[^b^](#tid13348-note-0006){ref-type="fn"}      NA              312.5[^b^](#tid13348-note-0006){ref-type="fn"}
  Day 3 after TCZ                                                                     NA               NA               188.7[^a^](#tid13348-note-0005){ref-type="fn"}   564.5[^b^](#tid13348-note-0006){ref-type="fn"}    NA              282.7[^b^](#tid13348-note-0006){ref-type="fn"}
  At last f/up                                                                        NA               NA               63.3[^a^](#tid13348-note-0005){ref-type="fn"}    1077.6[^b^](#tid13348-note-0006){ref-type="fn"}   NA              NA
  Pa02/Fi02 (mm Hg)                                                                                                                                                                                                                        
  Before TCZ                                                                          115              291              333                                              300                                               83              182
  Day 3 after TCZ                                                                     135              203              256                                              111                                               291             265
  At last f/up                                                                        92               87               493                                              170                                               347             187

Abbreviations: FiO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen; TCZ, tocilizumab.

Normal range 0‐4.4.

Normal range 2‐29.
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![Therapeutic timeline for anti‐COVID‐19 and immunosuppressant medications in our case series. DAR/RIT, darunavir/ritonavir; HCQ, hydroxychloroquine; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MP, methylprednisolone; TAC, tacrolimus; TCZ, tocilizumab](TID-9999-e13348-g001){#tid13348-fig-0001}

2.1. Patient 1 {#tid13348-sec-0003}
--------------

41‐year‐old patient. He received kidney transplant from deceased donor 15 years ago. Ongoing immunosuppressive therapy was composed by tacrolimus (TAC) and prednisone.

After few days of fever and cough, patient was tested positive for COVID‐19 on 03/25/2020. TAC was immediately discontinued while glucocorticoids (methylprednisolone 20 mg daily) were maintained. In the same day of the diagnosis, hydroxycloroquine and antiviral treatment (darunavir/ritonavir 800/100 mg) were started, in association with antibiotic therapy (cefepime). On day 7 after diagnosis, because of rapid worsening of respiratory status, TCZ was administered and repeated in day 8; concomitantly, according to progressive deterioration of kidney function and difficult management of fluid overload, continuous renal‐replacement therapy (CRRT) was initiated. Despite the antibiotic therapy implementation with azithromycin, respiratory failure occurred needing mechanical ventilation from day 15; patient died two days after.

2.2. Patient 2 {#tid13348-sec-0004}
--------------

65‐year‐old patient. He received kidney transplant from a deceased donor on March 2020. A negative COVID‐19 test was obtained before kidney transplant, and no positive contact with COVID‐19 subjects was reported in the days before KT.

Induction immunosuppressive therapy was composed by thymoglobulin (for three days) and methylprednisolone, and subsequent maintenance therapy included TAC (levels 10‐12 ng/mL), mycophenolate mofetil (MMF) and prednisone. Patient also received ganciclovir for CMV prophylaxis (CMV IgG‐/donor CMV IgG+).

Eight days after KT patient experienced fever and cough; swab test was subsequently repeated and resulted positive. Immunosuppressive medications (TAC, MMF) were immediately stopped, except of glucocorticoids (methylprednisolone 20 mg/d). Patient started hydroxycloroquine (200 mg daily) and darunavir/ritonavir (800/100 mg daily) the day after and remained hemodynamically stable with only slow reduction of peripheral oxygen saturation (94%‐95% with low‐flow oxygen through nasal cannula); TCZ was administered on day 4 and 5.

On day 6, arterial pO2 decreased and patient started non‐invasive ventilation (NIV); after a further deterioration of pulmonary status, mechanical ventilation was needed from day 7.

On day 8, blood and urinary cultures were both positive for multi‐sensitive Klebsiella Pneumoniae (urinary culture was also positive for Enterococcus Faecalis), and antibiotic treatment was shifted from amoxicillin/clavulanic acid to cefepime.

Despite progressive modifications on antibiotic therapy (with at least adoption of gentamicin, piperacillin/tazobactam, and daptomycin), fluid and medication support patient became oliguric (starting CRRT from day 12) and died on day 17.

2.3. Patient 3 {#tid13348-sec-0005}
--------------

54‐year‐old patient. He received his third kidney transplant in 2014. Ongoing immunosuppressive therapy was composed by TAC and glucocorticoids. On 04/03/2020, patient experienced fever, emesis, and diarrhea and tested positive for COVID‐19. TAC was immediately discontinued, and only methylprednisolone 20 mg/daily was maintained in association of hydroxycloroquine (200 mg/d). On day 2, hemophtysis and worsening of respiratory status occurred. Oral anticoagulant therapy (in patient with mechanical aortic valve) was stopped and replaced by low‐molecular‐weight heparin, and non‐invasive ventilation (NIV) was started. TCZ was administered on day 2 and 3. On day 12, after an improvement in respiratory condition, NIV was suspended; patient was discharged on day 20. Currently (26 days after discharge), he recovered to normal pulmonary functional status, keeping only steroids (prednisone 25 mg/d) as immunosuppressive therapy.

2.4. Patient 4 {#tid13348-sec-0006}
--------------

62‐year‐old patient. He performed his second KT on 2007. Immunosuppressive therapy was composed by TAC, MMF, and steroids. On 03/22/2020, patient experienced fever, dyspnea, and diarrhea and then tested positive for COVID‐19. TAC and MMF were immediately discontinued. Hydroxycloroquine 200 mg daily, methylprednisolone 20 mg daily, and piperacillin‐tazobactam, in association to fluconazole, were started. A rapid worsening of respiratory status was observed from day 1 after diagnosis, needing mechanical ventilation. TCZ was administered (8 mg/kg) on day 16; respiratory status showed no improvement and patient deceased on day 26.

2.5. Patient 5 {#tid13348-sec-0007}
--------------

49‐year‐old patient. He received kidney transplant 18 years ago. Ongoing immunosuppressive therapy was TAC, MMF, and glucocorticoids. On 03/24/2020, he was admitted to the Emergency Department because fever and cough from two days. After positive swab test, TAC level was reduced, MMF was stopped, and hydroxycloroquine (200 mg/d) plus antibiotic therapy (ceftaroline) was started.

On day 4, after progressive worsening of respiratory status, TAC was discontinued and NIV plus TCZ were started. On day 11, IVIg (0.2 g/kg/d) was also administered for four consecutive days. On day 16, glucocorticoid therapy was increased with methylprednisolone 40 mg twice daily. NIV was discontinued on day 17 and the patient was discharged on day 21 after diagnosis.

Currently (12 days after discharge), pulmonary function recovered to basal patient\'s status and TAC target through level are progressively increased to 4‐5 ng/mL with glucocorticoids maintained.

2.6. Patient 6 {#tid13348-sec-0008}
--------------

62‐year‐old patient. He received KT in 2011. Ongoing immunosuppressive therapy was composed by TAC and glucocorticoids. Patient was admitted to Emergency Department on 04/03/2020 because of fever and dyspnea. After diagnosis of COVID‐19 pneumonia, TAC was stopped on day 1 and treatment with hydroxycloroquine (200 mg daily) and amoxicillin‐clavulanic acid (1 g twice daily) were started, in association with methylprednisolone 20 mg daily. Mechanical ventilation was also initiated on day 1; TCZ was administered on day 2 and 3. Despite all supportive therapies, pulmonary function rapidly declined and patient deceased on day 8 after diagnosis.

3. DISCUSSION {#tid13348-sec-0009}
=============

COVID‐19 is now considered as the most prominent health‐care problem around the world.[^13^](#tid13348-bib-0013){ref-type="ref"} Emerging data highlight the role of comorbid conditions (hypertension, diabetes, cardiovascular disease) and older age as major determinants of negative outcome.[^10^](#tid13348-bib-0010){ref-type="ref"} Recently, kidney disease has also been associated with increased in‐hospital mortality.[^14^](#tid13348-bib-0014){ref-type="ref"}

Transplant patients, due to the combination of this frail profile associated with immunosuppressive medications, are considered a high‐risk population[^15^](#tid13348-bib-0015){ref-type="ref"}; despite preventive strategies and medication protocols are urgently needed, definite guidelines for KT are not currently established and different and specular approaches have so far been reported.

Some group suggest the immediately withdrawn of immunosuppressive drugs with only steroid maintenance,[^1^](#tid13348-bib-0001){ref-type="ref"}, [^16^](#tid13348-bib-0016){ref-type="ref"} despite steroid use is controversial and associated with reduced viral clearance.[^17^](#tid13348-bib-0017){ref-type="ref"} Other authors report a possible antiviral effect of CNI inhibitors[^2^](#tid13348-bib-0002){ref-type="ref"}, [^4^](#tid13348-bib-0004){ref-type="ref"}, [^6^](#tid13348-bib-0006){ref-type="ref"}, [^10^](#tid13348-bib-0010){ref-type="ref"}, [^18^](#tid13348-bib-0018){ref-type="ref"} suggesting per contrast their maintenance in solid organ transplanted patients, especially in liver transplants. This theory is also supported by the evidence that ARDS occurred in patients with important inflammatory activation (the so‐called cytokine storm) and in this context immunosuppressive medications and anti‐inflammatory drug (ie, TCZ) may mitigate the damage. All these data are partially questioned by a recent US report[^19^](#tid13348-bib-0019){ref-type="ref"} were mortality in KT patients is extremely high compared to normal population, despite a recent Spanish case series detailed a more favorable picture[^20^](#tid13348-bib-0020){ref-type="ref"} ^.^

To date, few reports included TCZ‐treated kidney transplanted patients with COVID‐19 pneumonia[^12^](#tid13348-bib-0012){ref-type="ref"}, [^19^](#tid13348-bib-0019){ref-type="ref"}, [^20^](#tid13348-bib-0020){ref-type="ref"}, [^21^](#tid13348-bib-0021){ref-type="ref"}, [^22^](#tid13348-bib-0022){ref-type="ref"}, [^23^](#tid13348-bib-0023){ref-type="ref"} (Table [3](#tid13348-tbl-0003){ref-type="table"}): In all these available experiences, inclusion criteria, dose, f/up, and outcome indicators were different, and a significant number of cases was still inpatients.

###### 

Kidney transplant recipients with COVID‐19 treated with tocilizumab (PubMed update on 05/09/2020)

+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+
| Author                                                           | Patients, n (studied population)                 | Criteria for tocilizumab adoption                                            | Dose, mg (n)                                                                          | Pulmonary outcome              | Patients outcome at last f/up |
+==================================================================+==================================================+==============================================================================+=======================================================================================+================================+===============================+
| Ferandez‐Ruiz et al[^21^](#tid13348-bib-0021){ref-type="ref"}    | 1 (1)                                            | Progressive respiratory failure + increasing inflammatory parameters         | 600 mg iv (one dose)                                                                  | Mild radiological improvement  | Inpatient                     |
+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+
| Alberici et al[^22^](#tid13348-bib-0022){ref-type="ref"}         | 6 (20)                                           | Worsening of respiratory infection                                           | 8 mg/kg iv, max 800 mg (two doses, intervals 12‐24 h)                                 | 3/6 reduced oxygen requirement | 3/6 inpatient                 |
|                                                                  |                                                  |                                                                              |                                                                                       |                                |                               |
|                                                                  |                                                  |                                                                              |                                                                                       | 2/6 radiological improvement   | 2/6 death                     |
|                                                                  |                                                  |                                                                              |                                                                                       |                                |                               |
|                                                                  |                                                  |                                                                              |                                                                                       |                                | 1/6 discharged                |
+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+
| Akalin et al[^19^](#tid13348-bib-0019){ref-type="ref"}           | 2 (28)[^a^](#tid13348-note-0008){ref-type="fn"}  | NA                                                                           | NA                                                                                    | NA                             | NA (10/28 discharged)         |
+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+
| Fontana et al[^12^](#tid13348-bib-0012){ref-type="ref"}          | 1 (1)                                            | PFT deterioration                                                            | 324 mg sc (one dose)                                                                  | Recovery                       | Discharged                    |
|                                                                  |                                                  |                                                                              |                                                                                       |                                |                               |
|                                                                  |                                                  | \+ elevated IL‐6                                                             |                                                                                       |                                |                               |
+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+
| Montagud‐Marrahi et al[^20^](#tid13348-bib-0020){ref-type="ref"} | 13 (26)[^a^](#tid13348-note-0008){ref-type="fn"} | NA                                                                           | NA                                                                                    | NA                             | NA (21/26 discharged)         |
+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+
| Pereira et al[^23^](#tid13348-bib-0023){ref-type="ref"}          | 14 (90)[^b^](#tid13348-note-0009){ref-type="fn"} | Rapid pulmonary decompensation due to high and deleterious cytokine activity | 400 mg sc or 8 mg/kg iv, max 800 mg (9/14 one dose, 4/14 two doses, 1/14 three doses) | NA                             | 3/14 death                    |
|                                                                  |                                                  |                                                                              |                                                                                       |                                |                               |
|                                                                  |                                                  |                                                                              |                                                                                       |                                | 4/14 inpatient (ICU)          |
|                                                                  |                                                  |                                                                              |                                                                                       |                                |                               |
|                                                                  |                                                  |                                                                              |                                                                                       |                                | 5/14 inpatient                |
|                                                                  |                                                  |                                                                              |                                                                                       |                                |                               |
|                                                                  |                                                  |                                                                              |                                                                                       |                                | 2/14 discharged               |
+------------------------------------------------------------------+--------------------------------------------------+------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+--------------------------------+-------------------------------+

Abbreviations: ICU, intensive care unit; iv, intravenous; NA, not available; sc, subcutaneous.

Inpatient group.

46/90 kidney tranplants.
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Despite different timing, in our case series TCZ was administered at the same dosage after deterioration of pulmonary status and contemporary evidence of significant inflammatory activation (increase C‐reactive protein and/or IL‐6, if available). The adoption of TCZ determined a C‐reactive protein reduction in all patients without significant modification in LDH or D‐Dimer; also IL‐6 decreased in the 2/3 patients with available test, albeit levels remain significantly upper the normal range. However, four out of six patients died; in the 2/6 who recovered a significant increase in lymphocyte count was observed, confirming that a restoration of lymphocyte activity is crucial for obtaining a favorable outcome.[^24^](#tid13348-bib-0024){ref-type="ref"}

We need to underline that some factors may be confounding in the analysis of the direct effect of TCZ: For example, sepsis may have concurred to death in patients 1, 4, and 6; however, as reported by other Authors, the virus caused a profound immunosuppression [^5^](#tid13348-bib-0005){ref-type="ref"}, [^11^](#tid13348-bib-0011){ref-type="ref"} and, in this context, the result of combined inhibition of IL‐6 receptor in predisposing to bacterial infections is not well understood. We also pointed out that we treated with TCZ only kidney transplanted patients who required hospitalization with significant reduction of pulmonary function and increase of inflammatory markers. At the time we are writing, 20 patients who received KTs in our Center were tested positive for COVID‐19, and 8/20 (including 4/8 who received TCZ) died. Because all patients with COVID‐19 who do not need hospitalization were tested and remained at home, we do not have laboratory/pulmonary functional markers to compare this cohort to TCZ‐treated patients.

In conclusion, despite these data should be evaluated with extremely caution and have some limitations (selection bias, availability of IL‐6 dosage in all patients, absence of CD4+/CD8 + count), our study confirmed that kidney transplanted patients are a high‐risk group with significant COVID‐19‐associated mortality. The evaluation of the TCZ effect in COVID‐19 pneumonia requires controlled studies (ideally RCTs) in this specific population.
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